Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies

Completed · Phase 2

Conditions studied: Pompe Disease Infantile-Onset, Glycogen Storage Disease Type II

In brief

This extension study was to monitor the long-term safety and efficacy of rhGAA treatment in patients with infantile-onset Pompe disease who were previously treated with rhGAA derived from the Synpac cell line

Key facts

Study ID
NCT00763932
Run by
Genzyme, a Sanofi Company
People needed
7
Starts
2003-04-01
Expected to finish
2006-07-01
Last updated by the study team
2014-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.